iCAD, Inc. Overview
Pro stress-test →iCAD is a global leader in AI-powered cancer detection solutions, primarily focused on breast cancer screening through its ProFound Breast Health Suite. The company serves thousands of healthcare providers globally across over 50 countries, having processed more than 40 million mammograms in the last five years. iCAD is transitioning to a cloud-based SaaS business model to enhance financial predictability and scalability.
Strategic Profile
Pro stress-test →iCAD differentiates itself through clinically proven AI algorithms for early cancer detection and personalized risk assessment, with strong R&D backing evidenced by FDA clearances and partnerships with radiologists. The company is strategically pivoting from traditional software licensing to cloud-based recurring revenue models (ProFound Cloud), positioning itself for higher-margin, more predictable revenue streams in the growing AI healthcare market.
Competitive Landscape
Pro stress-test →iCAD competes in the AI-powered medical imaging market against larger players with broader oncology portfolios and against point-solution competitors. Key competitors include companies offering AI diagnostic tools for breast cancer, cardiology, and general radiology. iCAD's advantage lies in focused domain expertise in breast cancer detection and established relationships with radiologists globally, though it faces competition from well-funded AI healthcare startups and major healthcare IT vendors.
Industry Context
iCAD, Inc. operates in Healthcare IT / AI Medical Imaging / Oncology Technology.
Key facts
Founded: 1984 · Headquarters: Nashua, New Hampshire, US · Employees: Unknown · Revenue: $4.9M · Market cap: $108M